Gaboxadol (HLX-0206) ( DrugBank: Gaboxadol )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 206 | 脆弱Ｘ症候群 | 1 |
206. 脆弱Ｘ症候群
臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04823052 (ClinicalTrials.gov) | May 25, 2022 | 24/3/2021 | Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40 | A Phase 2, Placebo-controlled, Adaptive Design Study to Explore the Safety and Efficacy of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) and Possible Other Treatments in Adolescent and Adult Males With Fragile X Syndrome (FXS) | Fragile X Syndrome | Drug: Sulindac (HLX-0201), dose strength 1;Drug: Sulindac (HLX-0201), dose strength 2;Drug: Placebo;Drug: Gaboxadol (HLX-0206) | Healx Limited | NULL | Withdrawn | 13 Years | 40 Years | Male | 0 | Phase 2 | United States;Australia |